| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/14/2013 | US20130041018 Method of treating acute myelogenous leukemia |
| 02/14/2013 | US20130041016 Compositions and Methods for Preventing and Treating Cancer via Modulating UBE1L, ISG215 and/or UBP43 |
| 02/14/2013 | US20130041015 Use of the Lactosylceramide Synthase Isoform B1,4GALT-V as a Biomarker for Cancer |
| 02/14/2013 | US20130041014 Isoform of bruton's tyrosine kinase (btk) protein |
| 02/14/2013 | US20130041013 Isoform of bruton's tyrosine kinase (btk) protein |
| 02/14/2013 | US20130041012 New isoform of bruton's tyrosine kinase (btk) protein |
| 02/14/2013 | US20130041008 Compounds for enzyme inhibition |
| 02/14/2013 | US20130041007 Selective Androgen Receptor Modulators |
| 02/14/2013 | US20130041005 Pharmaceutical compositions comprising neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers |
| 02/14/2013 | US20130041004 Liquid Formulations Of Bendamustine |
| 02/14/2013 | US20130041003 Bendamustine Pharmaceutical Compositions |
| 02/14/2013 | US20130041002 Denibulin di-hydrochloride |
| 02/14/2013 | US20130041000 Novel azole compound |
| 02/14/2013 | US20130040998 Fluorinated hdac inhibitors and uses thereof |
| 02/14/2013 | US20130040995 Novel compounds |
| 02/14/2013 | US20130040994 Methods of Treatment Using Allosteric Processing Inhibitors for Matrix Metalloproteinases |
| 02/14/2013 | US20130040986 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
| 02/14/2013 | US20130040983 Raf kinase inhibitors |
| 02/14/2013 | US20130040981 Pyridylvinylpyrazoloquinolines as PAR1 inhibitors |
| 02/14/2013 | US20130040980 Cci-779 concentrate formulations |
| 02/14/2013 | US20130040979 Ccr1 inhibitors useful for the treament of multiple myeloma and other disorders |
| 02/14/2013 | US20130040976 Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| 02/14/2013 | US20130040975 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 02/14/2013 | US20130040973 JAK PI3K/mTOR COMBINATION THERAPY |
| 02/14/2013 | US20130040972 USE OF c-Src INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA |
| 02/14/2013 | US20130040967 4'-demethylepipodophyllotoxin derivative, preparation method and use thereof |
| 02/14/2013 | US20130040964 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors |
| 02/14/2013 | US20130040962 P38 MAP Kinase Inhibitors |
| 02/14/2013 | US20130040958 Imatinib mesylate preparation procedure |
| 02/14/2013 | US20130040957 Deuterium-Enriched Pyrimidine Compounds and Derivatives |
| 02/14/2013 | US20130040956 Process for the preparation of stable, crystalline (6s)-n(5)-methyl-5,6,7,8-tetrahydrofolic acid |
| 02/14/2013 | US20130040951 Prophylactic or therapeutic agent for cancer |
| 02/14/2013 | US20130040950 Multisubstituted aromatic compounds as inhibitors of thrombin |
| 02/14/2013 | US20130040949 Type ii raf kinase inhibitors |
| 02/14/2013 | US20130040945 Certain chemical entities, compositions, and methods |
| 02/14/2013 | US20130040944 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| 02/14/2013 | US20130040943 Tricyclic pyridyl-vinyl pyrroles as par1 inhibitors |
| 02/14/2013 | US20130040940 Mercaptoamidine derivatives and methods of use |
| 02/14/2013 | US20130040935 Cyclic keto-enols for therapy |
| 02/14/2013 | US20130040934 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| 02/14/2013 | US20130040933 Azaindoles as janus kinase inhibitors |
| 02/14/2013 | US20130040928 Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics |
| 02/14/2013 | US20130040925 Osmium (ii) arene azo anti-cancer complexes |
| 02/14/2013 | US20130040924 Bridged polycyclic compound based compositions for the inhibition and amelioration of disease |
| 02/14/2013 | US20130040921 Anticancer steroidal lactones unsaturated in position 7 (8) |
| 02/14/2013 | US20130040916 Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
| 02/14/2013 | US20130040915 Pharmaceutical composition |
| 02/14/2013 | US20130040912 Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders |
| 02/14/2013 | US20130040909 Compositions including triciribine and one or more platinum compounds and methods of use thereof |
| 02/14/2013 | US20130040908 Substitution derivatives of n6-benzyladenosine-5' -monophosphate, methods of preparation thereof, use thereof as medicaments, and therapeutic preparations containing these compounds |
| 02/14/2013 | US20130040906 Inhibitors of Human EZH2, and Methods of Use Thereof |
| 02/14/2013 | US20130040905 Combination Of Drugs With Protein-Binding Prodrugs |
| 02/14/2013 | US20130040900 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/14/2013 | US20130040896 Methods and compositions for modulating angiogenesis and pericyte composition |
| 02/14/2013 | US20130040894 Inhibition or activation of serine/threonine ulk3 kinase activity |
| 02/14/2013 | US20130040893 Treatment of proliferative disorders |
| 02/14/2013 | US20130040892 Iap bir domain binding compounds |
| 02/14/2013 | US20130040876 Method for sensitizing cells to cancer therapy |
| 02/14/2013 | US20130040388 Cytostatic drug composition |
| 02/14/2013 | US20130039996 Potentiation of cancer chemotherapy by 7-(2, 5- dihydro- 4-imidazo [1, 2-a] pyridine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro -2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine |
| 02/14/2013 | US20130039989 Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide |
| 02/14/2013 | US20130039986 Silk-Based Ionomeric Compositions |
| 02/14/2013 | US20130039981 Quick Dissolving, Long Acting Zinc Therapeutic Formulations |
| 02/14/2013 | US20130039979 Medication on the basis of 3,3'-diindolylmethane (dim) with high-bioavailability and its use in treatment of human hyperplastic and inflammatory diseases |
| 02/14/2013 | US20130039974 Anti-muc1 antibodies for cancer diagnostics |
| 02/14/2013 | US20130039971 Compositions and methods for inhibition of vegf |
| 02/14/2013 | US20130039970 Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
| 02/14/2013 | US20130039953 Method for treating a surface with a coating comprising a therapeutic agent and device with treated surface |
| 02/14/2013 | US20130039942 Compositions and Methods for Self-Adjuvanting Vaccines against Microbes and Tumors |
| 02/14/2013 | US20130039940 Homogenous Vaccine Composition Comprising a Conjugate of EGF and P64K for the Treatment of Tumors |
| 02/14/2013 | US20130039939 Lipopeptide- and lipoprotein-conjugates and its use |
| 02/14/2013 | US20130039936 Immunogenic pote peptides and methods of use |
| 02/14/2013 | US20130039935 Induction of tumor immunity by variants of folate binding protein |
| 02/14/2013 | US20130039931 Antibodies Against A Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof |
| 02/14/2013 | US20130039930 Biomarker for sensitivity to therapy with a notch inhibitor |
| 02/14/2013 | US20130039929 Method treating breast cancer |
| 02/14/2013 | US20130039919 Novel plasminogen receptor, polypeptides and antibodies thereof |
| 02/14/2013 | US20130039918 Pharmaceutical Composition Using Connective-tissue Growth Factor |
| 02/14/2013 | US20130039917 Diagnostic and therapeutic target |
| 02/14/2013 | US20130039916 ENGINEERED ANTI-IL-23p19 ANTIBODIES |
| 02/14/2013 | US20130039915 Siglec 15 antibodies in treating bone loss-related disease |
| 02/14/2013 | US20130039913 Heterodimeric antibody fc-containing proteins and methods for production thereof |
| 02/14/2013 | US20130039912 Robo1-fc fusion protein and use thereof for treating tumours |
| 02/14/2013 | US20130039911 Compositions and Methods for Targeted Immunomodulatory Antibodies and Fusion Proteins |
| 02/14/2013 | US20130039910 Methods and compositions for modulating angiogenesis and pericyte composition |
| 02/14/2013 | US20130039909 Predicting response to a her inhibitor |
| 02/14/2013 | US20130039908 Prognostic markers and methods for prostate cancer |
| 02/14/2013 | US20130039907 Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow |
| 02/14/2013 | US20130039906 PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE |
| 02/14/2013 | US20130039904 Gambogic acid cyclization analogues, their preparation method and application thereof |
| 02/14/2013 | US20130039892 Adherent stromal cells derived from plancentas of multiple donors and uses thereof |
| 02/14/2013 | US20130039891 Poxviral oncolytic vectors |
| 02/14/2013 | US20130039890 Treatment of tumors with genetically engineered herpes virus |
| 02/14/2013 | US20130039886 Beta-mannosylceramide and stimulation of nkt cell anti-tumor immunity |
| 02/14/2013 | US20130039883 Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
| 02/14/2013 | US20130039880 Cyclodextrin-based polymers for therapeutics delivery |
| 02/14/2013 | US20130039857 Methods of suppressing cancer, increasing weight loss and/or increasing insulin sensitivity |
| 02/14/2013 | US20130039854 Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer |
| 02/14/2013 | US20130039853 Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| 02/14/2013 | US20130039852 Methods of targeting cells for diagnosis and therapy |